Q-omics provides the consensus-scored MIR1268A profile across patient tissues and cancer cell-line models. MIR1268A expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR1268A is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, MIR1268A RNA expression shows 6,212 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, COAD, and STAD as cancer lineages where MIR1268A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1268A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1268A survival associations across molecular data types. MIR1268A RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1268A RNA expression–survival associations across cancer types. High MIR1268A expression shows unfavorable associations in ACC, LAML, UCS, PCPG and SKCM, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR1268A RNA expression.
This table summarizes MIR1268A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1268A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1268A shows lower tumor expression in COAD and higher tumor expression in PAAD and LIHC. The COAD box plot shows higher MIR1268A RNA expression in normal versus tumor tissue (log2 FC = −1.083, t-test p < 0.001).
This table shows molecular features associated with MIR1268A in patient tissues and cancer cell lines. In patient samples, MIR1268A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
